Deep Branch Biotechnology is a technology company.
Deep Branch Biotechnology has raised $8.0M across 1 funding round.
Deep Branch Biotechnology has raised $8.0M in total across 1 funding round.
Deep Branch Biotechnology is a biotechnology company founded in 2018 that developed scalable technology to convert carbon dioxide from industrial waste gases into Proton™, a sustainable single-cell protein serving as an alternative to soy and fishmeal in animal feed for livestock and aquaculture.[1][3] It targets industrial emitters, reducing their carbon footprint while providing nutritious, low-impact feed ingredients to the agriculture sector, addressing food security and emissions challenges.[2][3] The company launched a pilot facility in 2024 for gas-to-feed production and gained recognition for its CO2 utilization tech, but as of late 2025, Deep Branch Biotechnology Ltd is in liquidation, with its registered office under advisory for insolvency proceedings.[4]
Deep Branch Biotechnology was incorporated on 31 July 2018 in Nottingham, United Kingdom, as a private limited company focused on research and experimental development in biotechnology (SIC code 72110).[1][4] Emerging from the need to repurpose industrial pollutants, the company pioneered microbe-based processes to transform CO2 and waste gases into high-value proteins, starting with small-scale operations (1-10 employees).[1][5] Early traction included partnerships like REACT-FIRST for CO2 utilization and press coverage on sustainable ventures, culminating in a pivotal 2024 pilot facility launch that advanced its "feed from gas" project; by 2025, it rebranded elements to Aerbio amid expansion mentions in Copenhagen and Dutch biotech events, though the core entity entered liquidation.[2][3][4]
Deep Branch rides the carbon capture and utilization (CCU) wave, leveraging industrial emissions as feedstock amid rising net-zero pressures and sustainable protein demand driven by aquaculture growth and soy deforestation concerns.[3][5] Timing aligns with 2020s policy pushes for biotech in circular economies, as seen in EU and UK funding for CO2 recycling, amplified by food security needs post-climate disruptions.[2] Market forces like volatile fishmeal prices and emitter regulations favor its model, influencing the ecosystem by validating gas-fermentation tech—paving the way for competitors and integrations in agribiotech, though its liquidation underscores scaling risks in deep tech.[1][4]
With liquidation underway, Deep Branch's IP and tech—especially Proton™ production—may live on via acquisition, rebranding (e.g., Aerbio), or tech transfer, fueling ongoing CO2-to-protein pilots.[2][4] Trends like advanced fermentation scale-up and carbon markets will shape successors, potentially amplifying influence in sustainable ag if integrated into larger players. This pivot from pioneer to asset echoes biotech's high-risk path, yet reinforces CCU's role in turning emissions into tomorrow's feeds—echoing its founding vision of polluters as producers.[1][3]
Deep Branch Biotechnology has raised $8.0M in total across 1 funding round.
Deep Branch Biotechnology's investors include Act Venture Capital, Verve Ventures.
Deep Branch Biotechnology has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $8.0M Series A | Act Venture Capital, Verve Ventures |